FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200300947> ?p ?o ?g. }

• W4200300947 abstract "Vascular calcification (VC), in which vascular smooth muscle cells (VSMCs) undergo differentiation and osteogenic transition, is a common complication of chronic kidney disease (CKD). Recent findings show that nuclear factor-erythroid-2-related factor 2 (NRF2) is an evolutionarily conserved antioxidant and beneficial in preventing vascular senescence and calcification. The roles of NRF2 in the initiation and progression of VC in CKD still need further investigation. CKD-associated VC model rats exhibited significant upregulation of NRF2, NAD(P)H: quinone oxidoreductase-1 (NQO1), osteogenic markers such as alkaline phosphatase (ALP), runt-related transcription factor-2 (RUNX2) and osteopontin (OPN), and β-catenin compared to CKD rats. Immunohistochemistry further verified these results. In addition, rat aortic VSMCs were isolated and subjected to four treatments: normal control, phosphorus-induced (Pi), Pi + NRF2 activator DMF, and Pi + NRF2 inhibitor ML385. The reactive oxygen species (ROS) generation, malondialdehyde (MDA) content, and calcium deposition of the four treatments were determined. The mRNA and protein expression levels of NRF2, NQO1, and haem oxygenase 1 (HO1) and the osteogenic markers ALP, Runx1, OPN, bone morphogenetic protein 2 (BMP2), and β-catenin were quantified by RT-PCR and western blotting. VSMC apoptosis was calculated by flow cytometry. The in vitro results suggested that intracellular oxidative stress and calcification were closely associated with NRF2 activity and that the activation of NRF2 could significantly suppress osteogenic transition and apoptosis in VSMCs. Thus, this study indicated that the NRF2-related antioxidant pathway can positively respond to and protect against the initiation and progression of VC in CKD by reducing oxidative stress. This study may contribute insights facilitating the application of the NRF2 antioxidative system as a therapeutic treatment for vascular diseases such as CKD." @default.
• W4200300947 created "2021-12-31" @default.
• W4200300947 creator A5027002421 @default.
• W4200300947 creator A5040711000 @default.
• W4200300947 creator A5041609722 @default.
• W4200300947 creator A5042064075 @default.
• W4200300947 creator A5065704116 @default.
• W4200300947 creator A5075634571 @default.
• W4200300947 date "2021-12-17" @default.
• W4200300947 modified "2023-09-30" @default.
• W4200300947 title "NRF2‐suppressed vascular calcification by regulating the antioxidant pathway in chronic kidney disease" @default.
• W4200300947 cites W1588127651 @default.
• W4200300947 cites W1970882491 @default.
• W4200300947 cites W1974257350 @default.
• W4200300947 cites W1979055405 @default.
• W4200300947 cites W1983946999 @default.
• W4200300947 cites W1986430910 @default.
• W4200300947 cites W1987117656 @default.
• W4200300947 cites W1991265255 @default.
• W4200300947 cites W2000607329 @default.
• W4200300947 cites W2031004071 @default.
• W4200300947 cites W2064327102 @default.
• W4200300947 cites W2080572398 @default.
• W4200300947 cites W2083847691 @default.
• W4200300947 cites W2089358094 @default.
• W4200300947 cites W2108116509 @default.
• W4200300947 cites W2114164409 @default.
• W4200300947 cites W2117800935 @default.
• W4200300947 cites W2124591820 @default.
• W4200300947 cites W2146662079 @default.
• W4200300947 cites W2171742547 @default.
• W4200300947 cites W2204607192 @default.
• W4200300947 cites W2550881001 @default.
• W4200300947 cites W2560778433 @default.
• W4200300947 cites W2614450303 @default.
• W4200300947 cites W2726121826 @default.
• W4200300947 cites W2761586844 @default.
• W4200300947 cites W2790654167 @default.
• W4200300947 cites W2794139372 @default.
• W4200300947 cites W2942699224 @default.
• W4200300947 cites W2954937777 @default.
• W4200300947 cites W2960009181 @default.
• W4200300947 cites W2968513998 @default.
• W4200300947 cites W2969381862 @default.
• W4200300947 cites W2970532676 @default.
• W4200300947 cites W2984323265 @default.
• W4200300947 cites W2997481362 @default.
• W4200300947 cites W3008841114 @default.
• W4200300947 cites W3015858898 @default.
• W4200300947 cites W3046885739 @default.
• W4200300947 cites W3089557761 @default.
• W4200300947 cites W3092439568 @default.
• W4200300947 cites W3107561854 @default.
• W4200300947 doi "https://doi.org/10.1096/fj.202100625rr" @default.
• W4200300947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34918390" @default.
• W4200300947 hasPublicationYear "2021" @default.
• W4200300947 type Work @default.
• W4200300947 citedByCount "11" @default.
• W4200300947 countsByYear W42003009472022 @default.
• W4200300947 countsByYear W42003009472023 @default.
• W4200300947 crossrefType "journal-article" @default.
• W4200300947 hasAuthorship W4200300947A5027002421 @default.
• W4200300947 hasAuthorship W4200300947A5040711000 @default.
• W4200300947 hasAuthorship W4200300947A5041609722 @default.
• W4200300947 hasAuthorship W4200300947A5042064075 @default.
• W4200300947 hasAuthorship W4200300947A5065704116 @default.
• W4200300947 hasAuthorship W4200300947A5075634571 @default.
• W4200300947 hasConcept C104317684 @default.
• W4200300947 hasConcept C126322002 @default.
• W4200300947 hasConcept C127561419 @default.
• W4200300947 hasConcept C134018914 @default.
• W4200300947 hasConcept C160160445 @default.
• W4200300947 hasConcept C181199279 @default.
• W4200300947 hasConcept C185592680 @default.
• W4200300947 hasConcept C190283241 @default.
• W4200300947 hasConcept C2776151105 @default.
• W4200300947 hasConcept C2776363554 @default.
• W4200300947 hasConcept C2778401633 @default.
• W4200300947 hasConcept C2779395532 @default.
• W4200300947 hasConcept C2780309369 @default.
• W4200300947 hasConcept C2780804394 @default.
• W4200300947 hasConcept C2992686903 @default.
• W4200300947 hasConcept C48349386 @default.
• W4200300947 hasConcept C55493867 @default.
• W4200300947 hasConcept C71924100 @default.
• W4200300947 hasConcept C86803240 @default.
• W4200300947 hasConceptScore W4200300947C104317684 @default.
• W4200300947 hasConceptScore W4200300947C126322002 @default.
• W4200300947 hasConceptScore W4200300947C127561419 @default.
• W4200300947 hasConceptScore W4200300947C134018914 @default.
• W4200300947 hasConceptScore W4200300947C160160445 @default.
• W4200300947 hasConceptScore W4200300947C181199279 @default.
• W4200300947 hasConceptScore W4200300947C185592680 @default.
• W4200300947 hasConceptScore W4200300947C190283241 @default.
• W4200300947 hasConceptScore W4200300947C2776151105 @default.
• W4200300947 hasConceptScore W4200300947C2776363554 @default.
• W4200300947 hasConceptScore W4200300947C2778401633 @default.
• W4200300947 hasConceptScore W4200300947C2779395532 @default.
• W4200300947 hasConceptScore W4200300947C2780309369 @default.
• W4200300947 hasConceptScore W4200300947C2780804394 @default.

• next